Black Diamond Therapeutics, Aterian, and Biodexa Pharmaceuticals are the 3 Penny Stocks to watch on March 20, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are defined as stocks that trade at or below $5 per share and have a market capitalization of below $300 million.
The Penny Stock Screener helps investors scan stocks based on numerous parameters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to pick the top three penny stocks with the highest Dollar Volume as of the close on March 19, 2025. Simply put, Dollar Volume is the number of shares traded on a particular day multiplied by the day’s share price.
Black Diamond Therapeutics (BDTX) – Black Diamond Therapeutics is a clinical-stage oncology company engaged in developing its proprietary therapies to address families of oncogenic mutations in clinically validated targets. On March 19, BDTX had a Dollar Volume of $197.05 million, while its stock price rose by 2.4%. BDTX stock is trending higher in pre-market trading, up 13.9% at the time of writing.
Black Diamond announced a global licensing agreement with pharmaceutical group Servier for its lead drug candidate, BDTX-4933. Per the deal, Servier will develop and commercialize the drug. BDTX will receive an upfront payment of $70 million and another $710 million along with royalties in future payments contingent on meeting certain development sales milestones. Shares are trending higher in reaction to this news.
Aterian (ATER) – Aterian operates an e-commerce portal offering a wide range of consumer goods, including home and kitchen appliances, wellness products, and electronics through its six foundational brands. ATER had a Dollar Volume of $137.63 million yesterday, while its stock price surged by nearly 28%.
ATER stock jumped after the company announced better-than-expected earnings and revenues for Q4FY24. Aterian also provided an optimistic revenue outlook for Fiscal 2025 and announced a $3 million stock buyback program, effective through March 18, 2027.
Biodexa Pharmaceuticals PLC (BDRX) – Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company, developing innovative treatments for serious diseases such as familial adenomatous polyposis (FAP), type 1 diabetes, and primary and metastatic cancers of the brain. On March 19, BDRX’s Dollar Volume stood at $89.71 million, accompanied by a stock price jump of 16.1%.
The company announced that it is on track to initiate a Phase 3 trial for eRapa targeted for treatment of FAP next quarter. Biodexa has also received a Fast Track designation from the FDA (Food and Drug Administration), conducted a Type C meeting with the FDA, and appointed a clinical research organization (CRO) to conduct the European component of its registrational Phase 3 trial. Investors are reacting positively to this news.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.
Questions or Comments about the article? Write to editor@tipranks.com